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• Prostate and bladder cancers are the first and fourth most common 
noncutaneous cancers in men in developed nations
• Plasma is also called the fourth state of matter
• Ionized gas composed of reactive species, electrical and excited particles
• Cold plasmas recently came into the attention of medical society due to its 
non-inflammatory selective ablative effects in tumour cells
• Their effects result from different interactions between plasma components with 
specific structural cell elements as well as cell functionalities
• Their selectivity of action results from the lower antioxidant defenses of tumor cells and 
the cell cycle block at phase G2/M in rapidly multiplying cells
• Plasma therapy is still a developing field, but it seems to be effective against a 
wide range of tumors – melanoma, glioblastoma, breast, colon, lung and 
cervix cancer
• Little is known about its role in the treatment of urologic neoplasms
• Goal: The aim of this work was to evaluate the cytotoxicity of cold 
atmospheric plasma (CAP) in prostate and urinary bladder cancer cell lines
• CAP is effective on LNCaP and HT1376 cells – over 90% decrease in metabolic activity and protein content after only 60s of exposure
• Regarding to PC3 prostate cancer cell line, there was a decrease in metabolic activity after 60 seconds similar to the other two tumor lines, but the protein content 
did not have the same reaction even with 120s of exposure
• For the same exposure conditions, there was less change din metabolic activity or protein content of the normal fibroblast line
• CAP may offer a selective anti-tumour therapy capable of providing ablation of tumours after short time courses, typically in the range of seconds-minutes, without 
damaging with adjacent normal tissues
• Further studies are needed to determine the utility of CAP in the treatment of bladder and prostate cancer
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• Our group developed an electronic device capable of generating high output 
voltage that can ionize a significant fraction of air particles producing cold 
atmospheric plasma (CAP)
• Cell lines - plated in a concentration of 50.000-100.000 cells/mL in 200pL of 
cell culture medium
• Prostate adenocarcinoma - LNCaP and PC3
• Urinary bladder carcinoma - HT1376
• Phenotypically normal human fibroblasts cell line - HFF-1
• The device was designed to expose cell cultures seeded in multiwell plates to 
short periods of CAP
• Range from 15 to 120 seconds
• Metabolic activity (MA) and protein content (P) were assessed with 
colorimetric assays MTT and SRB, respectively
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Figure 1 - MTT assay results 24 h after plasma therapy application in different human cell
lines: prostate adenocarcinoma (PC3 and LNCap), urinary bladder carcinoma (HT1376) and
fibroblasts (HFF1) at distinct times: 15, 30, 60, 90 and 120 seconds (s). Results are
expressed as percentage of metabolic activity normalized to control.
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Figure 2 - SRB assay results 24 h after plasma therapy application in different human cell
lines: prostate adenocarcinoma (PC3 andLNCap), urinary bladder carcinoma (HT1376) and
fibroblasts (HFF1) at distinct times: 15, 30, 60, 90 and 120 seconds (s). Results are
expressed as percentage of protein content normalized to control.
